CAS: 65847-85-0; 2-Morpholinoethyl 2-((3-(Trifluoromethyl)Phenyl)Amino)Nicotinate

上下游产品

CAS号128699-18-3 2-chloronicotin... | CAS号98-16-8 间三氟甲苯胺

📜2-Chloronicotinic Acid (2-Morpholinoethyl) Ester,间氨基三氟甲苯置于碘体系中,用 5,5-Dimethyl-1,3-Cyclohexadiene,二氯甲烷,异丙醇 作为反应溶剂,以35%的收率获得产物吗尼氟酯
参考文献:Processes For The Preparation Of Morniflumate And Analogous Compounds
标题:Processes For The Preparation Of Morniflumate And Analogous Compounds
摘要:描述了用于制备莫尼氟酸和类似化合物的新型工艺,这些工艺能够直接获得产品的自由碱形式,采用简化的合成方案,并且产率显著高于先前工艺获得的产率.本发明的工艺对于工业应用尤为有利.

专利信息

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人：WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-7504409-B2
优先权日:2000-01-31
标 题:Mucin synthesis inhibitors
发明人：ZHOU YUHONG; LEVITT ROY C; NICOLAIDES NICHOLAS C; JONES STEVE; MCLANE MIKE
权利人:GENAERA CORP
摘要:The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

专利号:US-2005249675-A1
优先权日:2003-06-19
标 题 :Mucin synthesis inhibitors
发明人：HUNG HSIAO-LING; CHELLQUIST ERIC; LEVITT ROY C; MCLANE MICHAEL
权利人:HUNG HSIAO-LING; CHELLQUIST ERIC; LEVITT ROY C; MCLANE MICHAEL
摘要:The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

专利号:US-7345051-B2
优先权日:2000-01-31
标题 :Mucin synthesis inhibitors
发明人：ZHOU YUHONG; LEVITT ROY C; NICOLAIDES NICHOLAS C; JONES STEVE; MCLANE MIKE
权利人:GENAERA CORP
摘要:The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases. n nwhereinn X is S, N, O or CR; Y is CRR′, O, NR 6 , CRR′—CRR′ or CRâ•?CR; Z is NR 6 , O, S, CRR′ or CRR′—CRR′; R 1 -R 3 are independently selected from the group consisting of H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, amino, hydroxy, halosubstituted alky and halo; R 4 is n n n n n n n n n n n n n n n n n n n Q is CR, NR 6 or n n n n n n n n n n n n R 5 is H or benzyl; n R 6 is H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, OH or halo; and n R and R′ are independently H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, OH or halo,n nor a harmaceutically acceptable salt thereof.

专利号:US-2002147216-A1
优先权日:2000-01-31
标 题:Mucin synthesis inhibitors
发明人：ZHOU YUHONG; LEVITT ROY C; NICOLAIDES NICHOLAS C; JONES STEPHEN; MCLANE MIKE
摘要:The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

专利号:US-2002165244-A1
优先权日:2000-01-31
标 题 :Mucin synthesis inhibitors
发明人：ZHOU YUHONG; LEVITT ROY C; NICOLAIDES NICHOLAS C; JONES STEVE; MCLANE MIKE
摘要:The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.